Anticancer dose

The mode of action of a whole class of anticancer drugs has been revealed by Johns Hopkins scientists. Gregg Semenza and colleagues have vindicated the high-frequency low-dose regime for anthracyclines proposed by Judah Folkman in 2000 and known as the metronomic treatment. The class includes the common anticancer agents doxorubicin, daunorubicin, epirubicin, and idarubicin, which have been used since the 1960s for treating leukemia, lymphoma, sarcomas, and carcinomas.